Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth.

about

Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth.

Item

http://www.wikidata.org/entity/Q45887217

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@en

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@nl

type

Item

label

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@en

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@nl

prefLabel

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@en

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@nl

P1476

Intratumoral administration of ...... ErbB-2 inhibits tumor growth.

@en

P2093

Emtage P

http://www.w3.org/2001/XMLSchema#string

Gauldie J

http://www.w3.org/2001/XMLSchema#string

Muller WJ

http://www.w3.org/2001/XMLSchema#string

Palmer K

http://www.w3.org/2001/XMLSchema#string

Sharan N

http://www.w3.org/2001/XMLSchema#string

Wan Y

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Role of HER2 gene overexpression in breast carcinoma.

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Targeted tumor killing via an intracellular antibody against erbB-2.

Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.

Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors

Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

P2888

sj.gt.3301712

P304

898-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.GT.3301712

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11295511

http://www.w3.org/2001/XMLSchema#string

P6179

1015461574

http://www.w3.org/2001/XMLSchema#string

P698

12080384

http://www.w3.org/2001/XMLSchema#string

P921

Adenoviridae